But so far, so good for the TROP2-directed treatment, which is off to a "smooth market launch,” according to Daiichi CEO ...

At the World Conference on Lung Cancer (WCLC), Gilead unveiled data from its phase 2 EVOKE-02 study of already-approved TROP2 drug Trodelvy (sacituzumab govitecan), showing what it said was ...

Antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan) for triple-negative breast cancer and urothelial added a $118 million in the quarter following its approvals last April, just about ...